MK-677 and hunger: what the ghrelin data actually shows

What did @diagofit.daily1 actually say?

The creator describes MK-677 as "the hunger drug" and walks through a personal timeline: fatigue and mild hunger on day one, then by day three, hunger that persists even after a full meal, including waking at 3 a.m. with what they call "stomach in panic mode." They also claim users "fill out," sleep deeply, and recover "like you're on gear," while insisting MK-677 is not a steroid. The central thesis is that MK-677 "builds you in between the sets," meaning it drives recovery rather than acute performance. That's the actual argument. Let's take it apart.

Does the science back this up?

On hunger, yes, strongly. On recovery and sleep quality, there's real data. On the framing that this is some secret, not so much.

MK-677 (ibutamoren) is a ghrelin receptor agonist and growth hormone secretagogue. Its appetite effects are well-documented and not subtle. Nass et al. (2008, Journal of Clinical Endocrinology and Metabolism) found that MK-677 increased GH and IGF-1 levels while also significantly stimulating appetite in older adults. The ghrelin mimicry is the mechanism here: ghrelin is your hunger hormone, and MK-677 essentially keeps it activated. Waking up hungry at 3 a.m. is not surprising given how the compound works pharmacologically.

On sleep, there is legitimate data. Copinschi et al. (1997, Sleep) demonstrated that MK-677 increased REM sleep duration and improved sleep quality in healthy young adults and older subjects. The creator's "sleep like a corpse" line is hyperbolic, but it's pointing at a real effect. On muscle and body composition, Murphy et al. (1998, Journal of Clinical Endocrinology and Metabolism) showed increased fat-free mass in elderly subjects after MK-677 administration. Recovery-adjacent effects, particularly through elevated IGF-1, are biologically plausible.

What did they get wrong (or right)?

They got the hunger and sleep effects directionally right. They got the "not a steroid" distinction right in a technical sense. Where things get sloppy is the timeline and the word "secret."

The claim that by "day three, you're starving" is anecdotal and compresses a pharmacological timeline in a way that's hard to validate from published data. Individual responses vary considerably. More importantly, the creator skips entirely over the side effect profile that matters most: fluid retention, increased cortisol, and potential insulin resistance. Smith et al. (2005, Endocrine) flagged increased fasting glucose and cortisol as consistent findings in MK-677 users. That's not a minor footnote. For anyone with metabolic concerns, that's a clinically relevant risk.

The framing of MK-677 as building you "in between the sets" is actually a reasonable lay explanation of how growth hormone secretagogues work, primarily through protein synthesis and recovery signaling rather than direct in-workout performance. That part deserves credit. What doesn't is the omission of the full picture.

What should you actually know?

MK-677 is not approved by the FDA for any indication in healthy adults. It is not a peptide in the traditional sense. It is an orally active, non-peptide ghrelin mimetic. That distinction matters because it affects how it's regulated, sourced, and what quality controls exist for compounded or gray-market versions.

The appetite amplification the creator describes is real, but it cuts both ways. If you are in a caloric surplus trying to build muscle, that hunger signal might be useful. If you are trying to manage body composition carefully, persistent hunger that overrides satiety cues is a liability, not a feature. The creator presents this entirely as a positive without acknowledging that context.

There are also longer-term unknowns. Most human studies on MK-677 run 6 to 24 months and involve older populations or growth hormone-deficient patients, not healthy young adults using it for bodybuilding. Extrapolating those results to a 22-year-old running it for aesthetics involves assumptions the data does not support. Anyone considering this compound should have a real conversation with a licensed provider who can review bloodwork, including fasting glucose and IGF-1 levels, before and during use.